EUSICA / INSICA Position Paper on Squamous Cell Carcinoma of the Nasal Vestibule: A Distinct Clinical Entity Requiring Dedicated Classification, Treatment Strategies and Outcome Measures

ABSTRACT Purpose Cancer of the nasal vestibule (CNV) differs anatomically and clinically from both sinonasal and cutaneous squamous cell carcinoma, yet lacks formal recognition as a separate clinical entity and topographical subsite; whether it is also biologically distinct has not yet been investigated. EUSICA/INSICA advocates for formal recognition of CNV and a unified classification, treatment, and translational framework. Method Published literature on CNV, including population‐based cohorts, T‐classification studies, brachytherapy outcomes, and quality‐of‐life data, was reviewed by an international multidisciplinary EUSICA/INSICA expert panel to formulate consensus recommendations. Finding CNV shows favorable outcomes, drains preferentially to facial and submandibular nodes, and is amenable to organ‐preserving radiotherapy, in particular brachytherapy. It is staged using four non‐uniform systems; multicenter validation in 609 patients from 21 centers supported the prognostic utility of the New Rome classification integrated with clinical nodal status. Validated CNV‐specific quality‐of‐life instruments are lacking. Compared with NCCN‐defined high‐risk cutaneous SCC of the nose, CNV differs in topography, pattern of local spread, prognostic landmarks, nodal behavior, and treatment paradigm. Comparative molecular data versus cutaneous and sinonasal SCC are not yet available. Conclusion EUSICA/INSICA calls for formal recognition of CNV as a distinct ICD‐O‐3 subsite, incorporation of the New Rome T classification into UICC/AJCC TNM, standardized organ‐preserving treatment, and dedicated translational research, including comparative molecular studies to determine whether its clinical distinctness has a biological basis.

Authors

Institutions

Publication Details

Journal
Head & Neck
Published
2026-11-16
DOI
https://doi.org/10.1002/hed.70552
Primary Topic
Head and Neck Surgical Oncology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

EUSICA / INSICA Position Paper on Squamous Cell Carcinoma of the Nasal Vestibule: A Distinct Clinical Entity Requiring Dedicated Classification, Treatment Strategies and Outcome Measures

Matt Lechner, Garret W. Choby, Mario Turri–Zanoni, Antoine Moya‐Plana et al.
Head & Neck
Head and Neck Surgical Oncology
article

EUSICA / INSICA Position Paper on Squamous Cell Carcinoma of the Nasal Vestibule: A Distinct Clinical Entity Requiring Dedicated Classification, Treatment Strategies and Outcome Measures

Matt Lechner, Garret W. Choby, Mario Turri–Zanoni, Antoine Moya‐Plana, Paolo Bossi, Marlene Maria Speth, Glenn J. Hanna, David Capper, Jana Zajacovà, Robbie Woods, Nyall R. London, Annalisa Trama, Francesco Bussu, Sandra Nuyts, Juliette Thariat, Benjamin Vérillaud, Christian von Buchwald, Ehab Y. Hanna, Mischa de Ridder, Mario A. J. A. Hermsen, Gerben Eise Breimer, Lot A. Devriese, Johannes Adriaan Rijken, Gary L. Gallia, François‐Régis Ferrand
article en

Abstract

ABSTRACT Purpose Cancer of the nasal vestibule (CNV) differs anatomically and clinically from both sinonasal and cutaneous squamous cell carcinoma, yet lacks formal recognition as a separate clinical entity and topographical subsite; whether it is also biologically distinct has not yet been investigated. EUSICA/INSICA advocates for formal recognition of CNV and a unified classification, treatment, and translational framework. Method Published literature on CNV, including population‐based cohorts, T‐classification studies, brachytherapy outcomes, and quality‐of‐life data, was reviewed by an international multidisciplinary EUSICA/INSICA expert panel to formulate consensus recommendations. Finding CNV shows favorable outcomes, drains preferentially to facial and submandibular nodes, and is amenable to organ‐preserving radiotherapy, in particular brachytherapy. It is staged using four non‐uniform systems; multicenter validation in 609 patients from 21 centers supported the prognostic utility of the New Rome classification integrated with clinical nodal status. Validated CNV‐specific quality‐of‐life instruments are lacking. Compared with NCCN‐defined high‐risk cutaneous SCC of the nose, CNV differs in topography, pattern of local spread, prognostic landmarks, nodal behavior, and treatment paradigm. Comparative molecular data versus cutaneous and sinonasal SCC are not yet available. Conclusion EUSICA/INSICA calls for formal recognition of CNV as a distinct ICD‐O‐3 subsite, incorporation of the New Rome T classification into UICC/AJCC TNM, standardized organ‐preserving treatment, and dedicated translational research, including comparative molecular studies to determine whether its clinical distinctness has a biological basis.

Head & Neck
University of Insubria (IT), University of Copenhagen (DK), National Institutes of Health (US), Humanitas University (IT), The University of Texas MD Anderson Cancer Center (US), Royal College of Surgeons in Ireland (IE), Johns Hopkins University (US), Inserm (FR), University of Sassari (IT), École Nationale Supérieure d'Ingénieurs de Caen (FR), Université Paris Cité (FR), Azienda Ospedaliera San Giovanni Addolorata (IT), Universitair Ziekenhuis Leuven (BE), Institut Gustave Roussy (FR), Copenhagen University Hospital (DK), TUM Klinikum (DE), Rigshospitalet (DK), University Medical Center Utrecht (NL), Humboldt-Universität zu Berlin (DE), Laboratoire de Physique Corpusculaire de Caen (FR), Dana-Farber Cancer Institute (US), Hôpital Lariboisière (FR), Centre François Baclesse (FR), Azienda Socio Sanitaria Territoriale Lariana (IT), Institut National de Physique Nucléaire et de Physique des Particules (FR), University of Pittsburgh Medical Center (US), National Cancer Institute (US), Center for Cancer Research (US), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), IRCCS Humanitas Research Hospital (IT), Instituto de Investigación Sanitaria del Principado de Asturias (ES), Deutsches Konsortium für Translationale Krebsforschung (DE), Fondation Gustave Roussy (FR), University College London (GB), Technical University of Munich (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), Université de Caen Normandie (FR)
Head and Neck Surgical Oncology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon